Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression

R Waziry, B Hajarizadeh, J Grebely, J Amin, M Law… - Journal of …, 2017 - Elsevier
Background & Aims The risk of hepatocellular carcinoma (HCC) occurrence or recurrence
following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. The …
被引用次数：531 相关文章

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression

R Waziry, B Hajarizadeh, J Grebely… - Journal of …, 2017 - researchers.mq.edu.au
Background & Aims: The risk of hepatocellular carcinoma (HCC) occurrence or recurrence
following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. The …

[引用][C] Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression

R Waziry, B Hajarizadeh, J Grebely, J Amin… - Journal of …, 2017 - cir.nii.ac.jp
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review,
meta-analyses, and meta-regression | CiNii Research CiNii 国立情報学研究所 学術情報 …

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.

R Waziry, B Hajarizadeh, J Grebely, J Amin… - Journal of …, 2017 - europepmc.org
Methods A search was conducted for reports published between January 2000 and
February 2017. Studies were included if they assessed HCC outcomes by type and …

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression.

R Waziry, B Hajarizadeh, J Grebely, J Amin, M Law… - 2017 - cabidigitallibrary.org
Background & aims: The risk of hepatocellular carcinoma (HCC) occurrence or recurrence
following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. The …

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression

R Waziry, B Hajarizadeh, J Grebely… - Journal of …, 2017 - journal-of-hepatology.eu
Background & Aims The risk of hepatocellular carcinoma (HCC) occurrence or recurrence
following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. The …

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression

R Waziry, B Hajarizadeh, J Grebely… - Journal of …, 2017 - pubmed.ncbi.nlm.nih.gov
Background & aims The risk of hepatocellular carcinoma (HCC) occurrence or recurrence
following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. The …

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression

R Waziry, B Hajarizadeh, J Grebely, J Amin, M Law… - journal-of-hepatology.eu
I Follow-up duration, HCC occurrence rates and confidence intervals were rounded to one
decimal place. a Ogawa 2013, the total number of patients= 1,013 among which 150 had …